Stock chart
Analyses on Pulsenmore (4)
- March 30, 2026March 30, 2026
- Follow-up
Pulsenmore: Can FC become a real second commercial engine
Pulsenmore’s FC has moved from clinical feasibility into a first real commercialization path, but at this stage it is still a Clalit-centered proof framework rather than a mature second revenue engine.
- Follow-up
Pulsenmore: How long can the balance sheet fund the U.S. push
Pulsenmore's balance sheet offers roughly two years of runway on the 2025 liquidity profile, but that runway is being financed out of existing cash rather than by a commercialization model that is already funding itself.
- Follow-up
Pulsenmore: What really remains of 2025 after stripping out GE
After stripping out the GE component, Pulsenmore did not finish 2025 with a new revenue engine. It finished with a nearly flat operating base, weaker underlying gross profit, and a core operating loss still sitting around NIS 43 million.
Pulsenmore 2025: The GE Settlement Cleaned Up the P&L, but the Proof Year Starts Now
Pulsenmore closed the GE chapter in 2025 and opened the U.S. door, but the underlying business barely grew, so 2026 is a commercialization proof year rather than a proven breakout year.
